EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieÄquivalenzstudieOpen Access · CC BY 4.0

Amoxicillin vs. placebo to reduce symptoms in children with group A streptococcal pharyngitis: a randomized, multicenter, double-blind, non-inferiority trial

Renato Gualtieri, Charlotte Verolet, Chiara Mardegan, Sébastien Papis, Natasha Loevy, Sandra Asner, Marie Rohr, Juan Llor, Ulrich Heininger, Laurence Lacroix, Laure F Pittet, Klara M Posfay-Barbe

European Journal of Pediatrics · 2024

DOI: 10.1007/s00431-024-05705-1 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Pediatrics, 2024. Verfasst von Renato Gualtieri und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of General Pediatrics, Department of Pediatrics, Gynaecology and Obstetrics, Geneva University Children's Hospital and University of Geneva,…. Hauptthemen laut MEDLINE: Pharyngitis, Amoxicillin, Streptococcal Infections, Anti-Bacterial Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hôpitaux Universitaires de Genève, Société Académique de Genève, Gertrude von Meissner-Stiftung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The efficacy of antibiotic therapy for group A streptococcus (GAS) pharyngitis is debated. The role of antibiotics in preventing complications seems limited, with the main potential benefit being symptom duration reduction. Our study aimed to evaluate whether a placebo is non-inferior to amoxicillin in reducing fever duration. We randomized 88 children between 3 and 15 years of age presenting with acute symptoms of pharyngitis and a positive rapid antigen detection test for GAS to receive 6-day treatment with either placebo ( n = 46) or amoxicillin ( n = 42). The primary outcome was the difference in fever duration, with a non-inferiority threshold set at 12 h. The secondary outcomes included pain intensity and complications of streptococcal pharyngitis. The mean difference in fever duration between the amoxicillin and placebo groups was 2.0 h (95% CI, − 8.3 to 12.3) in the per-protocol analysis and 2.8 h (95% CI, − 6.5 to 12.2) in the intention-to-treat analysis. Treatment failure was observed in six participants in the placebo group and two in the amoxicillin group (relative risk, 2.15; 95% CI, 0.44–10.57). All patients were identified early and recovered well. There was no clinically relevant difference in pain intensity between groups over the 7 days following randomization, with the largest difference of 0.5 (95% CI, − 0.62–1.80) observed on day 3.

Conclusion

Placebo appears to be non-inferior to amoxicillin in reducing fever duration. Pain intensity and risk of complications were similar between the two groups. These findings support the restrictive antibiotic treatment for streptococcal pharyngitis. What is Known: • Group A streptococcus pharyngitis is a common reason for prescribing antibiotics in pediatric care. • In high-income countries, while antibiotic treatment has not been effective in preventing non-suppurative complications, the primary justification for their use remains the reduction of symptoms. What is New: • Our results suggest that antibiotics have a limited impact on the duration of fever and the intensity of pain in children with streptococcal pharyngitis. • Considering that suppurative complications can be promptly treated if they arise, we recommend a more judicious approach to antibiotic prescriptions.

Trial registration

The trial is registered at the US National Institutes of Health (ClinicalTrials.gov) # NCT03264911 on 15.08.2017.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PharyngitisAmoxicillinStreptococcal InfectionsAnti-Bacterial AgentsStreptococcus pyogenesHumansFemaleChildDouble-Blind MethodMaleChild, PreschoolAdolescentTreatment Outcome

Stichwörter der Autor:innen

AmoxicillinGroup A StreptococcusPlaceboStreptococcal pharyngitis

Substanzen

AmoxicillinAnti-Bacterial Agents

Autor:innen und Institutionen

  • Division of General Pediatrics, Department of Pediatrics, Gynaecology and Obstetrics, Geneva University Children's Hospital and University of Geneva, Geneva, Switzerland.
  • Pediatric Infectious Diseases and Vaccinology Unit, Lausanne University Hospital, Lausanne, Switzerland.
  • Pediatric Infectious Diseases Unit, Geneva University Children's Hospital and University of Geneva, Geneva, Switzerland.
  • Department of Pediatrics, Sion Hospital, Centre Hospitalier du Valais Romand, Sion, Switzerland.
  • Department of Pediatric Infectious Diseases and Vaccinology, University Children's Hospital Basel, Basel, Switzerland.
  • Department of Pediatric Emergency Medicine, Geneva University Children's Hospital and University of Geneva, Geneva, Switzerland.

Förderung

  • Hôpitaux Universitaires de Genève
  • Société Académique de Genève
  • Gertrude von Meissner-Stiftung
  • University of Geneva

Zitieren

APA

Gualtieri, R., Verolet, C., Mardegan, C., Papis, S., Loevy, N., Asner, S., Rohr, M., Llor, J., Heininger, U., Lacroix, L., Pittet, L. F., & Posfay-Barbe, K. M. (2024). Amoxicillin vs. placebo to reduce symptoms in children with group A streptococcal pharyngitis: a randomized, multicenter, double-blind, non-inferiority trial. European Journal of Pediatrics. https://doi.org/10.1007/s00431-024-05705-1

Vancouver

Gualtieri R, Verolet C, Mardegan C, Papis S, Loevy N, Asner S, et al. Amoxicillin vs. placebo to reduce symptoms in children with group A streptococcal pharyngitis: a randomized, multicenter, double-blind, non-inferiority trial. European Journal of Pediatrics. 2024. doi:10.1007/s00431-024-05705-1

BibTeX
@article{Gualtieri2024,
  author = {Gualtieri, Renato and Verolet, Charlotte and Mardegan, Chiara and Papis, Sébastien and Loevy, Natasha and Asner, Sandra and Rohr, Marie and Llor, Juan and Heininger, Ulrich and Lacroix, Laurence and Pittet, Laure F and Posfay-Barbe, Klara M},
  title = {Amoxicillin vs. placebo to reduce symptoms in children with group A streptococcal pharyngitis: a randomized, multicenter, double-blind, non-inferiority trial},
  journal = {European Journal of Pediatrics},
  year = {2024},
  doi = {10.1007/s00431-024-05705-1}
}
Kostenlos starten →